Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.26 USD | +11.37% | +22.07% | +169.20% |
May. 07 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
May. 06 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+169.20% | 667M | |
+28.98% | 49.18B | |
+0.86% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.17% | 26.09B | |
-22.70% | 18.71B | |
+8.13% | 13.26B | |
+32.09% | 12.32B | |
-0.71% | 11.99B |
- Stock Market
- Equities
- STOK Stock
- News Stoke Therapeutics, Inc.
- Stoke Therapeutics Secures UK Regulator's Approval to Initiate Phase 1/2 Study of STK-002